Sensei Biotherapeutics Statistics
Total Valuation
SNSE has a market cap or net worth of $11.33 million. The enterprise value is -$31.21 million.
Important Dates
The next estimated earnings date is Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SNSE has 25.15 million shares outstanding. The number of shares has decreased by -14.70% in one year.
| Current Share Class | 25.15M |
| Shares Outstanding | 25.15M |
| Shares Change (YoY) | -14.70% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | 9.40% |
| Float | 16.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.84, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.84 |
| Quick Ratio | 8.64 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -313.29 |
Financial Efficiency
Return on equity (ROE) is -51.04% and return on invested capital (ROIC) is -31.81%.
| Return on Equity (ROE) | -51.04% |
| Return on Assets (ROA) | -30.19% |
| Return on Invested Capital (ROIC) | -31.81% |
| Return on Capital Employed (ROCE) | -68.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.06M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.75% in the last 52 weeks. The beta is 0.17, so SNSE's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -40.75% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 38.47 |
| Average Volume (20 Days) | 169,430 |
Short Selling Information
The latest short interest is 266,470, so 1.06% of the outstanding shares have been sold short.
| Short Interest | 266,470 |
| Short Previous Month | 757,819 |
| Short % of Shares Out | 1.06% |
| Short % of Float | 1.61% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.58M |
| Pretax Income | -29.67M |
| Net Income | -29.80M |
| EBITDA | -31.26M |
| EBIT | -32.58M |
| Earnings Per Share (EPS) | -$1.19 |
Full Income StatementBalance Sheet
The company has $47.00 million in cash and $4.47 million in debt, giving a net cash position of $42.53 million or $1.69 per share.
| Cash & Cash Equivalents | 47.00M |
| Total Debt | 4.47M |
| Net Cash | 42.53M |
| Net Cash Per Share | $1.69 |
| Equity (Book Value) | 45.78M |
| Book Value Per Share | 1.82 |
| Working Capital | 42.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.04 million and capital expenditures -$146,000, giving a free cash flow of -$25.19 million.
| Operating Cash Flow | -25.04M |
| Capital Expenditures | -146,000 |
| Free Cash Flow | -25.19M |
| FCF Per Share | -$1.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |